NR3C2 and hydrops fetalis: Moreover, recent advances in HF and renal protective therapies, such as sacubitril–valsartan, sodium–glucose cotransporter 2 inhibitors, and new mineralocorticoid receptor antagonists, may affect the results of the present study [23].